In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene-Based Prodrug Nanoparticles.

Fiche publication

Date publication

février 2018

Journal

Advanced healthcare materials

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KLYMCHENKO Andrey

Tous les auteurs :
Cayre F, Mura S, Andreiuk B, Sobot D, Gouazou S, Desmaële D, Klymchenko AS, Couvreur P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29195020

Résumé

Förster resonance energy transfer (FRET) is used here for the first time to monitor the in vivo fate of nanoparticles made of the squalene-gemcitabine prodrug and two novel derivatives of squalene with the cyanine dyes 5.5 and 7.5, which behave as efficient FRET pair in the NIR region. Following intravenous administration, nanoparticles initially accumulate in the liver, then they show loss of their integrity within 2 h and clearance of the squalene bioconjugates is observed within 24 h. Such awareness is a key prerequisite before introduction into clinical settings.